TD Cowen Reiterates Buy Rating on Astria Therapeutics (ATXS)

TD Cowen analyst Stacy Ku reiterated a Buy rating and $35.00 price target on Astria Therapeutics (NASDAQ: ATXS).

The analyst commented, "Astria has established POC for navenibart/STAR-0215, with competitive efficacy in HAE prophylaxis. Our consultants are enthusiastic given the impressive efficacy/safety profile, and the meaningful improvement in administration burden/quality of life via Q3M/Q6M dosing. We expect key catalysts in H2 should increase investor conviction in the potential for Q6M dosing, and opportunity for '310."

For an analyst ratings summary and ratings history on Astria Therapeutics click here. For more ratings news on Astria Therapeutics click here.

Shares of Astria Therapeutics closed at $9.76 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy